UniTriTeam unveils AI tool for eSource study builds

By AI, Created 4:49 PM UTC, May 18, 2026, /AGP/ – UniTriTeam says its new ProtocolWeave platform will help clinical research sites standardize eSource study builds, with a full release set for July 1 and a limited beta now open. The company says the AI system uses private infrastructure, human review and USDM-aligned output to reduce manual work and speed study startup.

Why it matters: - Clinical research sites still spend significant time manually translating protocols into study builds, which can drive rework, slow startup and strain site staff. - UniTriTeam is pitching ProtocolWeave as a way to make that process more consistent while keeping human validation and data controls in place. - The platform targets a common operational bottleneck across sites, site networks and CRO partners.

What happened: - UniTriTeam announced ProtocolWeave™, an AI-powered solution for simplifying and standardizing eSource study builds for clinical research. - The platform is scheduled for full release on July 1, with a limited beta program open now for select sites, site networks and CRO partners. - UniTriTeam developed and owns ProtocolWeave, with ELEKS serving as the development partner.

The details: - ProtocolWeave functions as an AI-powered protocol analysis engine. - The system ingests study protocols and supporting documents, extracts clinically relevant data and generates a structured eSource specification for downstream use in CTMS and eSource platforms. - The output aligns with Unified Study Definitions Model protocol standards. - Every output goes through required human review before operational use. - UniTriTeam says that review layer adds validation, accountability and traceability. - The platform has already been tested against real clinical trial protocols. - Internal modeling suggests ProtocolWeave could significantly reduce eSource build timelines, with further validation continuing through the beta program. - ProtocolWeave runs on private, enterprise-grade infrastructure within Microsoft Azure. - Each organization gets a dedicated, isolated AI environment. - Data stays within each site or partner environment and is not used to train or inform models outside that controlled setting. - UniTriTeam says the goal is to make AI usable in clinical research without adding risk around sensitive information.

Between the lines: - The launch reflects a broader push to move clinical trial operations from manual workflows to standardized, software-supported processes. - Human validation is a key part of the pitch, signaling that adoption in regulated research may depend on keeping AI assistance inside tightly controlled review processes. - ELEKS brings more than 30 years of healthcare software engineering experience, while UniTriTeam brings site-side operational experience. - The partnership suggests UniTriTeam is positioning ProtocolWeave as both a workflow tool and a compliance-oriented product.

What’s next: - UniTriTeam is accepting applications for the limited beta program ahead of the July 1 launch. - The first release focuses on eSource, but UniTriTeam plans to expand ProtocolWeave into visit schedules, financial structuring and deeper integrations across clinical research platforms. - The beta program will help validate performance before broader deployment. - More information, Instagram, and Facebook

The bottom line: - UniTriTeam is trying to turn a manual, inconsistent study-build process into a standardized AI workflow with guardrails, and the company is betting that speed and data control can coexist in regulated clinical research.